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Abstract The L-amyloid (AL) peptide has previously been
shown to enhance phenylephrine or endothelin-1 induced
constriction of aortic rings in vitro. The characteristics of AL
vasoactivity (dose, fragment length, timing) suggest that the
mechanism is distinct from AL cytotoxicity. To identify which
properties of AL determine its biological activity on vessels, we
investigated a number of AL analogues and fragments,
individually and in combination, including those that are known
to be associated with Alzheimer’s disease (AL1ÿ42) and
hereditary cerebral hemorrhage with amyloidosis ^ Dutch type
(AL(22Q)1ÿ40). The vasoactivity appears to be related to the
conformation adopted by the peptide in solution. The L-pleated
sheet rich AL1ÿ42 and AL(22Q)1ÿ40 were each less vasoactive
than the mainly random coil wild type AL1ÿ40. However, the
most vasoactive AL peptides were combinations which contain
mixtures of random coil and L-sheet structure. The finding that
peptides containing low or high levels of L-pleated conformation
are less vasoactive than those containing intermediate amounts of
this structural motif allows us to propose the existence of a
transitional form between random coil and L-pleated that is the
vasoactive species of AL. This is the first time that AL
conformational intermediates have been identified and a
biological activity associated with them.
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1. Introduction
Cerebral amyloid angiopathy (CAA) is increasingly recog-
nized as a common cause of hemorrhage in the elderly and is
one of the pathological features of Alzheimer’s disease. Dep-
osition of L-amyloid (AL) peptide in the adventitia of cerebral
vessels progresses to invasion of the media with destruction of
the smooth muscle cells of that layer [1]. In a phenotypically
closely related condition, hereditary cerebral hemorrhage with
amyloidosis ^ Dutch type (HCHWA-D), both a genetic var-
iant of the AL peptide (AL22Q) and the wild type AL are
deposited in the walls of the cerebrovasculature [2]. In both
CAA and HCHWA-D the AL1ÿ40 peptide, rather than the
AL1ÿ42, is the predominant form deposited in vessels [3,4].
In cell culture experiments, AL peptides, including
AL(22Q)1ÿ40 are cytotoxic to components of the vessel wall
^ endothelial and smooth muscle cells [5,6].
We have previously demonstrated AL vasoactivity within
minutes of application of lower doses of AL1ÿ40 (50 nM^1
WM) than those used in cytotoxicity experiments. In rings of
rat aorta enhancement of phenylephrine or endothelin-1 con-
striction occurs when freshly solubilized peptide is applied
[7,8]. Pre-treatment with freshly solubilized AL1ÿ40 enhances
the vasoconstriction due to physiologic doses of endothelin-1,
while AL1ÿ42 demonstrates a decreased tendency to enhance
and no vasoactivity is observed with AL25ÿ35 [8]. The di¡erent
degrees to which AL peptides of di¡erent length, composition
and conformational propensity enhance vasoconstriction sug-
gested to us that there may be a relationship between AL
conformation and vasoactivity. Therefore we extended our
observations by testing the activity of other AL analogues
with di¡erent conformational propensities. We also examined
the e¡ects of mixing wild type AL1ÿ40 with either the L-sheet
rich Dutch AL(22Q)1ÿ40 or AL1ÿ42, and mixing AL1ÿ42 with
Dutch AL(22Q)1ÿ40.
2. Materials and methods
2.1. Vasoactivity assay
Vasoconstriction was measured in aortic rings from normal male
Sprague-Dawley rats using a tissue bath system as previously de-
scribed [7], and enhancement of constriction induced by the major
cerebral vasoregulator endothelin-1 (ET-1). Following a 2 h equilibra-
tion we used a range of doses of ET-1 (0.5, 1, 2, 3, 4 and 5 nM) for
pre-treatment constriction of the rings. After a further 2 h of equili-
bration, freshly solubilized peptide was added to the system. The
following peptide concentrations were used: 1 WM wild type
AL1ÿ40 ; 1 WM AL(22Q)1ÿ40 ; 1 WM AL1ÿ42 ; 0.5 WM wild type
AL1ÿ40 and 0.5 WM AL(22Q)1ÿ40 mixed; 0.5 WM AL1ÿ42 and 0.5 WM
AL(22Q)1ÿ40 mixed; 0.5 WM wild type AL1ÿ40 and 0.5 WM AL1ÿ42
mixed; 1 WM AL25ÿ35, 1 WM AL22ÿ35, 1 WM AL1ÿ28 or no peptide.
The post-treatment contraction was carried out using the same doses
of ET-1 as in the pre-contraction. AL1ÿ40 and AL1ÿ42 were purchased
from MD Enterprise; AL22ÿ35, AL1ÿ28 and AL25ÿ35 from Sigma; and
the AL(22Q)1ÿ40 peptide was obtained from WMKeck Foundation,
Yale University. The percentage contraction as compared to baseline
was determined for both the pre- and the post-treatment contractions
and the di¡erence between post- and pre- was calculated. The mean
di¡erence in percentage contraction at each ET-1 dose for each treat-
ment group was then calculated. At each dose of ET-1, all non-zero
control values for mean di¡erence in percent contraction were stand-
ardized to zero, and the values for other treatment groups were then
adjusted accordingly. Unadjusted data were analyzed by ANOVA and
by post-hoc comparison of the means using Sche¡eŁ’s correction for
multiple comparisons.
2.2. Circular dichroism (CD) studies
CD spectra were recorded on a Jasco spectropolarimeter Model
J-720 at room temperature in a 0.1 cm path-length cell. Stock solu-
tions of AL peptides were prepared in 50% acetonitrile and stored
lyophilized in aliquots. 50 Wg of each peptide was dissolved in 335 Wl
of 10 mM Tris, pH 7.4. For the experiments involving the combina-
tion of two AL variants, 25 Wg of each peptide was used. CD spectra
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Fig. 1. Vasoactivity of AL peptides. Aortic rings were constricted by addition of the doses of endothelin (ET-1) shown. Following equilibration,
1 WM of peptide or peptide combinations were added as indicated and the constriction repeated with the same ET-1 doses. The percentage in-
crease over baseline in the pre-treatment contraction was subtracted from the percentage increase over baseline in the post-treatment contrac-
tion and the mean di¡erence for each treatment at each dose was calculated and adjusted values (see text for details) were plotted as shown.
AL40wt = wild type AL1ÿ40 ; AL(22Q) = AL(22Q)1ÿ40 ; AL42 = AL1ÿ42. A: Enhancement of ET-1 vasoconstriction in the presence of AL1ÿ40
(P6 0.001 compared to controls), lesser enhancement with mutated AL(22Q)1ÿ40 (P = 0.03 compared to controls) and the signi¢cantly vasoac-
tive combination of wild type and mutated AL1ÿ40 (P = 0.01 compared to AL1ÿ40, and P6 0.001 compared to AL(22Q)1ÿ40). B: Similar results
with AL1ÿ42 which produces contractions signi¢cantly di¡erent from controls (P6 0.001) and when combined with AL(22Q)1ÿ40 is signi¢cantly
more vasoactive than AL(22Q)1ÿ40 alone (P = 0.003).
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were recorded 2 h after solubilization of the peptide and after centrif-
ugation to removed aggregated material. Forty scans were recorded at
0.2 nm intervals over the wavelength range 190^250 nm. Results are
expressed in terms of molar ellipticity in units of deg cm2 dmol31 and
the spectra analyzed by the Lincomb algorithm to estimate the per-
centages of the various secondary structure motifs [9].
3. Results and discussion
The in£uence of various AL analogues on vasoconstriction
of rat aortic rings was studied in the presence of ET-1. Wild
type AL1ÿ40 gave the expected enhancement of contraction
compared to controls (P6 0.001), while mutated
AL(22Q)1ÿ40 was also, to a lesser extent, signi¢cantly di¡erent
from untreated rings (P = 0.03). Enhancement of contraction
by wild type AL1ÿ40 was signi¢cantly di¡erent from that
caused by AL(22Q)1ÿ40 (P6 0.001). However, no individuals
have been reported who are homozygous for the Dutch mu-
tant, therefore we mixed freshly solubilized wild type AL1ÿ40
and AL(22Q)1ÿ40 in a 50:50 proportion at a ¢nal concentra-
tion of 1 WM. This combination produced enhancement of
vasoconstriction greater than that previously noted for any
AL peptide (Fig. 1A). Enhancement by this mixture was sig-
ni¢cantly higher than that produced by AL(22Q) alone
(P6 0.001) or by wild type AL1ÿ40 alone (P = 0.01). This
prompted us to compare the vasoactivity of other fragments
of AL of di¡ering amyloidogenic potential individually and in
combination. AL25ÿ35 has previously been reported by us to
not enhance ET-1 vasoconstriction [8]. In these experiments,
AL25ÿ35, AL22ÿ35 and AL1ÿ28 peptides did not di¡er signi¢-
cantly from one another, and furthermore were not signi¢-
cantly di¡erent from controls (data not shown). AL1ÿ42 also
enhanced vasoactivity as expected compared to untreated
rings (P6 0.001) [8]. The combination of AL1ÿ42 and
AL(22Q)1ÿ40 in a 50:50 proportion at ¢nal concentration of
1 WM, produced contractions which were signi¢cantly higher
than AL(22Q) alone (P = 0.003), and showed a tendency to be
higher than AL1ÿ42 alone (Fig. 1B). Similarly, a 50:50 mixture
of AL1ÿ40 with AL1ÿ42 also tended to be more vasoactive than
AL1ÿ42 alone (data not shown).
It has been shown that AL can adopt di¡erent conforma-
tions depending on the sequence, length of the peptide and
environmental conditions [10]. AL can exist in at least two
di¡erent conformational states, one more random coil/K-hel-
ical the other L-pleated [10], and the transition from K-helical/
random coil to the L-sheet form is well documented [11^13].
The AL conformations di¡er in several properties including
¢brillogenicity, neurotoxicity, resistance to proteolytic degra-
dation and interaction with amyloid-associated proteins
[10,11,14,15]. In order to study whether the di¡erences in vas-
oactivity of various AL analogues may have a conformational
basis, the secondary structure of the peptides and combina-
tions of peptides was evaluated by CD. As expected from
previous experiments [11], AL1ÿ40 has a mainly unordered
structure, while both AL(22Q)1ÿ40 and AL1ÿ42 are rich in L-
sheet conformation (Fig. 2A). The combination of AL1ÿ40
with AL(22Q)1ÿ40 or with AL1ÿ42, or of AL1ÿ42 with
AL(22Q)1ÿ40 produced intermediate spectra, indicating a mix-
ture between random coil and L-sheet structures. This result
could be interpreted as suggesting that the AL peptides did
not interact and the resulting CD spectrum corresponds to an
average between the spectra of each individual peptide. Alter-
natively, they may interact producing conformational changes
that give rise to a structural intermediate composed partially
of random coil and partially of L-sheet structure.
The latter explanation is supported by the relationship ob-
served between vasoactivity at the dose of ET-1 which gives
greatest separation between di¡erent AL analogues (3 nM),
and the L-sheet content of those same analogues (Fig. 2B).
The most vasoactive species was obtained in the combination
of AL1ÿ40 and AL(22Q)1ÿ40, which contains approximately
30% of L-sheet. If this percentage of L-structure were due to
a simple average between the L-sheet contents of the wild type
and Dutch peptides, it would be expected that the mixture
should produce an intermediate level of vasoconstriction.
Likewise the AL1ÿ42 and AL(22Q)1ÿ40 combination is signi¢-
cantly more vasoactive, but contains less L-sheet (approxi-
mately 50%) than either peptide individually (Fig. 2B).
We investigated the possible contribution of peptide po-
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Fig. 2. Relationship between vasoactivity and conformation of AL
peptides. A: Circular dichroism spectra of di¡erent AL variants
were recorded as described [12]. 50 Wg aliquots of each peptide were
dissolved in 335 Wl of 10 mM Tris, pH 7.4. For the experiments in-
volving the combination of two AL variants, 25 Wg of each peptide
was used. CD spectra were recorded 2 h after solubilization of the
peptide, in a Jasco spectropolarimeter, model J-720 at room temper-
ature in a 0.1 cm path-length cell. Forty scans were recorded at 0.2
nm intervals over the wavelength range 190^250 nm. Results are ex-
pressed in terms of molar ellipticity in units of deg cm2 dmol31. B:
The percentage of L-sheet content of each peptide and combinations
of peptides was estimated by analysis of CD spectra using the Lin-
comb algorithm [9] and plotted against the percentage of vasocon-
striction at 3 nM of endothelin-1, estimated as described in Fig. 1.
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lymerization to AL vasoactivity using sedimentation assays as
previously described [10], although it has previously been
demonstrated that at low concentrations and with short incu-
bation times AL can adopt distinct conformations without
changes in oligomerization stage [11]. Di¡erent AL variants
and peptide mixtures were incubated at the concentration and
bu¡er conditions used to study vasoactivity and secondary
structure. Under these conditions and at the time the vaso-
constriction and CD assays were carried out (2 h) there was
no signi¢cant peptide aggregation in any of the samples, as
assessed by centrifugation and peptide quantitation in the
supernatant. These results suggest that di¡erences in vasoac-
tivity are not due to distinct degrees of peptide polymeriza-
tion. We cannot rule out the possibility that slight di¡erences
in peptide oligomerization (such as dimers, tetramers, oc-
tamers, etc.) could contribute to the observed vasoactivity
and it is conceivable that heterodimeric or heteropolymeric
forms of the peptides, speci¢cally those created between wild
type AL1ÿ40 or AL1ÿ42 and AL(22Q)1ÿ40, are more vasoactive
than homodimers or homopolymers.
The ¢nding that peptides containing low or high levels of L-
sheet conformation are less vasoactive than those containing
intermediate amounts of L-sheet (Fig. 2B) leads us to propose
the existence of a transitional form between random coil and
L-pleated that is the vasoactive species of AL. To our knowl-
edge, this is the ¢rst time that a biological activity has been
associated with an AL conformational intermediate. In addi-
tion, the results showing that the mixture between AL1ÿ40 and
the less vasoactive AL(22Q)1ÿ40 or AL1ÿ42 produces a peptide
which exhibits high vasoactivity and intermediate conforma-
tion, indicate that di¡erent AL peptides could interact among
themselves and modify their properties.
It is possible that such interactions could modify the cyto-
toxic properties of these peptides in vascular cells. For exam-
ple, freshly solubilized AL1ÿ42 and AL(22Q)1ÿ40 are more
toxic to cerebrovascular smooth muscle cells than AL1ÿ40,
but increasing the L-sheet content of AL1ÿ42 by preaggrega-
tion abolishes the toxic e¡ects of AL1ÿ42 [16]. In human aortic
endothelial cells, freshly solubilized AL1ÿ42 is again more toxic
than AL1ÿ40, but while aging AL1ÿ40 increases the toxicity,
there is no e¡ect on AL1ÿ42 [5]. These data suggest that, as
with vasoactivity, toxicity of AL to vascular cells might be
modi¢ed by interaction between AL peptides of di¡ering L-
sheet content.
We have previously shown that the enhancement of vaso-
constriction by AL peptides is associated with rapid degener-
ation of the vessel wall [7], and these e¡ects of AL in rat
aortae have also been demonstrated in bovine middle cerebral
artery [17]. Both free radical and intracellular calcium levels
have been demonstrated to modify the e¡ects of AL [8], but
the mechanism of enhanced vasoconstriction or the accompa-
nying vessel damage in this experimental set-up is as yet un-
known. We hypothesize that in-life contact of AL peptides in
the vasoactive form with small cerebral vessels will increase
their tendency to constrict. The resultant subclinical ischemia
would be expected to up-regulate LAPP production in the
vasculature with further increase in AL formation. Such a
cycle of events would be expected to contribute to the destruc-
tion of cerebral vessels in both CAA and HCHWA-D. This
hypothesis is supported by the ¢ndings indicating that vascu-
lar amyloid deposits in HCHWA-D consist of a mixture of
wild type AL1ÿ40 (with small amounts of AL1ÿ42) and
AL(22Q)1ÿ40 [18]. Similarly, as the mutations responsible for
early onset familial Alzheimer’s disease all appear to result in
an increase in the production of the AL1ÿ42 fragment from
LAPP [19] one might postulate that AL1ÿ40/AL1ÿ42 peptide
mixtures are associated with the CAA observed in Alzheimer’s
disease. In any case, it seems clear that neither the normal
soluble form of AL nor the ¢brillar state are the most vaso-
active, but rather that a conformational intermediate is the
most vasoactive and thus potentially the most pathogenic spe-
cies.
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